Pfizer Inc and BioNTech SE on Wednesday said they had struck a deal for South Africa's Biovac Institute to process and distribute over 100 million doses a year of their Covid-19 vaccine for the African Union beginning in 2022. Technical transfer, on-site development and equipment installation activities will begin immediately, they said. Biovac, a public-private partnership focused on vaccine production, will receive Covid-19 vaccine drug substance made in plants in Europe, and will begin so-called fill-finish operations, the last stage of drug manufacturing and packaging, in 2022.
from Engineering News | Home https://ift.tt/3zzaN9N
